JLK-NCCT receives FDA 510(k) clearance for stroke triage alerts
Source publication date
Site published
The FDA letter identifies JLK-NCCT as Class II radiological triage and notification software and finds substantial equivalence to a legally marketed device. This is 510(k) clearance, distinct from premarket approval (PMA).
Its scope covers suspected intracranial hemorrhage and large-vessel occlusion involving the internal carotid artery and middle cerebral artery M1/M2 segments in adults. It sends mobile alerts alongside standard interpretation; compressed previews serve notification purposes.
The regulatory record does not establish hospital contracts or revenue. Clearance alone is not evidence of paid deployment.
Summary
The FDA cleared JLK-NCCT under 510(k) K252421 on March 24, 2026. The software flags suspected intracranial hemorrhage and large-vessel occlusion on adult non-contrast head CT scans.
Editorial view
Editorial view: expands the regulatory basis for U.S. commercialization. Paid contracts, actual use and product-level revenue remain separate business milestones.
Evidence and limitations
Not a primary diagnostic or rule-out tool. An absent alert does not exclude hemorrhage or occlusion, and the software does not replace CTA or MRA in ischemic-stroke workup.